In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile

OBJECTIVES: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). The objective was to determine the comparative susceptibility of 82 C. difficile clinical isolates (which included ribotype 027 isolates and isolates with reduced metr...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbett, D., Wise, A., Birchall, S., Warn, P., Baines, S. D., Crowther, G., Freeman, J., Chilton, C. H., Vernon, J., Wilcox, M. H., Vickers, R. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498293/
https://www.ncbi.nlm.nih.gov/pubmed/25652750
http://dx.doi.org/10.1093/jac/dkv006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498293/
https://www.ncbi.nlm.nih.gov/pubmed/25652750
http://dx.doi.org/10.1093/jac/dkv006

Ejemplares similares